Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider
Oslo, Norway, February 29, 2024 - Primary insider Michael Engsig, Chief
Executive Officer of Nykode Therapeutics ASA, has today acquired 6,000 shares in
Nykode Therapeutics ASA at a price of NOK 16.71 per share. Following the
transaction, Michael Engsig holds 15,850 shares in Nykode Therapeutics ASA.
Please see further details in the attached document.